| Basics |
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a clinical-stage pharmaceutical company dedicated to the development of pharmaceutical products to address public health challenges. Its drug development program is focused on delivering treatment for PTSD.
|
| IPO Date: |
June 1, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$231.29M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.24 | 4.45%
|
| Avg Daily Range (30 D): |
$0.64 | 3.76%
|
| Avg Daily Range (90 D): |
$1.30 | 4.22%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
7M |
| Avg Daily Volume (30 D): |
.68M |
| Avg Daily Volume (90 D): |
1.09M |
| Trade Size |
| Avg Trade Size (Sh.): |
708 |
| Avg Trade Size (Sh.) (30 D): |
92 |
| Avg Trade Size (Sh.) (90 D): |
81 |
| Institutional Trades |
| Total Inst.Trades: |
300 |
| Avg Inst. Trade: |
$1.59M |
| Avg Inst. Trade (30 D): |
$1.75M |
| Avg Inst. Trade (90 D): |
$1.65M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.05M |
| Avg Closing Trade (30 D): |
$.89M |
| Avg Closing Trade (90 D): |
$1.31M |
| Avg Closing Volume: |
39.93K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-3.59
|
$-3.86
|
$-2.84
|
|
Diluted EPS
|
$-3.59
|
$-3.86
|
$-2.84
|
|
Revenue
|
$ 3.29M
|
$ 2M
|
$ 2.43M
|
|
Gross Profit
|
$ 1.92M
|
$ -1.27M
|
$ 1.49M
|
|
Net Income / Loss
|
$ -32.01M
|
$ -28.27M
|
$ -16.83M
|
|
Operating Income / Loss
|
$ -33.07M
|
$ -28.3M
|
$ -16.05M
|
|
Cost of Revenue
|
$ 1.37M
|
$ 3.27M
|
$ .94M
|
|
Net Cash Flow
|
$ 65.11M
|
$ -6.38M
|
$ 32.94M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Feb 05, 2025:
1:100
|
|
Jun 10, 2024:
1:32
|
|
May 10, 2023:
4:25
|
|
May 17, 2022:
1:32
|
|
Nov 01, 2019:
1:10
|
|
Nov 28, 2018:
1:10
|
|
Mar 17, 2017:
1:10
|
|
May 01, 2013:
1:20
|
|
|
|
